NewLimit Raises $130M for Age Reversal
NewLimit, a biotech startup co-founded by Coinbase CEO Brian Armstrong, has secured $130 million in Series B funding. This significant investment follows a previous $40 million Series A round and underscores the growing interest in age-reversal therapies. The funding round was led by Kleiner Perkins, with participation from notable investors including Nat Friedman, Daniel Gross, and Khosla Ventures, alongside returning backers.
AI-Driven Drug Discovery
NewLimit's approach centers on genetically reprogramming cells to restore youthful characteristics. The company claims to have developed three prototype medicines that show promising results in rejuvenating liver cells, improving their ability to process fat and alcohol. Crucially, NewLimit utilizes an AI model to accelerate drug discovery. This "lab-in-a-loop" system simulates experiments, prioritizing the most promising candidates for laboratory testing and refining the AI model based on the results.
The Race for Lifespan Extension
While human trials remain some years away, NewLimit's progress highlights a broader trend in biotech: the pursuit of lifespan extension. The company joins other notable players like Retro Biosciences and Altos Labs in this ambitious field, all vying to develop treatments that could significantly extend healthy lifespans.
The substantial investment in NewLimit underscores the significant potential—and the considerable challenges—inherent in developing these groundbreaking therapies.
Source: TechCrunch